Martis Capital Invests in DCN Dx
November 19, 2020
Martis Capital has made a growth equity investment in DCN Dx, a Carlsbad, California-based lateral flow diagnostics developer and contract developer of rapid point-of-care tests. As part of the transaction, Charlie Mamrak will join DCN Dx as CEO; the capital will be used to accelerate growth and expand the company's diagnostic capabilities. Financial terms were not disclosed and Pegasus Capital and TM Capital advised on the deal.
- Buyers
- Martis Capital
- Targets
- DCN Dx
- Industry
- Medical Devices
- Location
- California, United States
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
Martis Capital acquires majority stake in Deerfield Group
June 30, 2026
Marketing & Advertising
Martis Capital Management acquired a majority equity stake in Deerfield Group, a healthcare marketing, communications, media, and technology agency focused on healthcare and life sciences clients. The investment is intended to accelerate Deerfield’s capability expansion, including deeper AI-enabled technology solutions and continued development of its service offerings, while founders and management retain significant ownership.
-
CareDx Acquires Naveris to Expand into Viral-Mediated Cancer MRD Testing
April 28, 2026
Healthcare Services
CareDx entered into a definitive agreement to acquire Naveris, a commercial-stage precision oncology diagnostics company, for $160 million upfront cash plus up to $100 million in revenue-based milestones. The acquisition extends CareDx’s precision medicine testing strategy into specialty oncology via Naveris’ NavDx liquid biopsy platform for viral-mediated cancers and MRD surveillance, with an anticipated close in Q3 2026 subject to customary conditions.
-
Martis Capital and Din Ventures Invest in Archway Dental Partners
January 19, 2024
Dental
Martis Capital and Din Ventures announced a growth investment in Archway Dental Partners, a Danbury, Connecticut-based dental partnership supporting 70 dentists across 23 locations. The capital will support Archway Dental's expansion as it aims to become a leading multi-specialty dental provider across New England and the Northeast.
-
DCN Dx Acquires Biomed Diagnostics
April 25, 2022
Healthcare Services
DCN Dx, a provider of point-of-use test development and commercialization, completed its acquisition of Biomed Diagnostics, a microbiological testing products company based in White City, Oregon. The deal expands DCN Dx’s footprint in point-of-use testing and sampling across both human and veterinary verticals.
-
DCN Dx Acquires PortaScience
June 17, 2021
Medical Devices
DCN Dx, a Carlsbad, California-based developer of point-of-care diagnostics, has completed the acquisition of PortaScience, Inc., a dry-chemistry focused point-of-care diagnostics development company based in Moorestown, New Jersey. The deal adds PortaScience's PortaCheck animal-health product line and expands DCN Dx's assay development, engineering, and product portfolio for healthcare, veterinary, and consumer diagnostics.
-
Ampersand Capital Partners Completes Growth Equity Investment in GenDx
May 8, 2019
Biotechnology
Ampersand Capital Partners completed a minority growth equity investment in Genome Diagnostics B.V. (GenDx), a Utrecht-based provider of molecular diagnostic kits and analysis software for transplantation and companion diagnostics. The partnership will support GenDx's organic growth and M&A strategy; Ampersand's David Parker and Operating Partner Mike Evans joined GenDx's board.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.